The role of VSNL1 in human heart rate regulation
VSNL1在人体心率调节中的作用
基本信息
- 批准号:10750747
- 负责人:
- 金额:$ 8.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-30 至 2025-09-29
- 项目状态:未结题
- 来源:
- 关键词:Action PotentialsAdrenergic AgentsAdrenergic AgonistsAdrenergic ReceptorAdrenergic beta-AntagonistsAffectAgonistArrhythmiaAtrial FunctionAttenuatedAutonomic nervous systemBiologicalBradycardiaCRISPR/Cas technologyCalciumCardiac conduction systemCardiovascular PhysiologyCardiovascular systemCell LineCell modelCell physiologyCellsCellular biologyCentral Nervous SystemCharacteristicsCholinergic AgonistsClinicalDataDerivation procedureDevelopmentElectrocardiogramElectrophysiology (science)EndocrineEtiologyExerciseGene Expression ProfilingGenerationsGenetic DatabasesGenetic EngineeringGenomicsGoalsHealthHeartHeart AtriumHeart RateHumanHuman ActivitiesIn VitroIndividualKnock-inKnock-outLeadLongevityMagnetic Resonance ImagingMapsMendelian randomizationMethodologyMethodsModelingMolecularMolecular ProfilingMorbidity - disease rateMuscle CellsNervous SystemNeurotransmitter ReceptorNeurotransmittersNodalOutcomePacemakersParticipantPatternPeriodicityPhenotypePhysiologicalPhysiologyPopulation GeneticsPrecision therapeuticsPrincipal InvestigatorProteinsProteomicsProtocols documentationRegulationReporterRestRoleSecondary toSignal PathwaySignal TransductionSinoatrial NodeStimulusStress TestsSystemTachycardiaTechnologyTestingTimeVSNL1 geneValidationVariantVentricularVentricular Functionbiobankcardiac magnetic resonance imagingcardiovascular effectscell typecholinergicclinical databaseclinical phenotypecohortdesigndifferentiation protocolembryonic stem cellepidemiology studygain of functiongenetic varianthuman datahuman embryonic stem cellhuman embryonic stem cell linein vitro Modelloss of functionmortalitynew therapeutic targetnodal myocytenull mutationparacrinepatch clampresponsesensorsingle-cell RNA sequencingstem cellstooltraffickingtranscriptomics
项目摘要
PROJECT SUMMARY
In the heart, pacemakers or sinoatrial node cells (SAN) initiate and maintain a rhythmic beating pattern that can
respond to external stimuli, including neurotransmitters, paracrine, and endocrine signals. In addition to its
clinical importance, resting heart rate is associated with lifespan across species, and has strong correlation with
longevity within individuals in several large epidemiologic studies. Despite their key role in human health and
physiology, the exact intracellular mechanism to maintain precise rhythmic oscillation is unknown, given the
limited access to these cells in the heart. The principal investigator hypothesizes that gene expression
analysis of the human sinoatrial node cell will identify cellular and physiologic features of human
pacemaking function. Recent technologies have enabled generating functional human SAN from embryonic
stem cells (hPSC-SAN) and performing molecular characterization at the single cell level. VSNL1, a calcium
sensing protein, was identified as a marker specific to SAN cells. I hypothesize that VSNL1 is uniquely
involved in heart rate regulation. Analyzing the genetic variants in VSNL1 gene and their effect on heart rate
in large biobanks will enable validation of the functional role of this protein in heart rate physiology. The applicant
will use large biobank cohorts and genetically engineered human embryonic stem cells to pursue the following
aims: First, determine the association between genetic variants in VSNL1 with cardiovascular physiology in
several large biobanks. Preliminary data in UK biobank (UKBB) cohort suggests significant association between
genetic variants in VSNL1 gene and baseline heart rate. The applicant will further study the effect of VSNL1
variants on heart rate with exercise, atrial and ventricular function (on cardiac MRI), and cardiovascular morbidity
and mortality outcomes in UKBB and other more diverse cohorts. Second, understand the effect of genetic
variants associated with heart rate in UKBB on molecular and electrophysiological characteristics of hPSC-SAN
cells in vitro. In preliminary data, the applicant has successfully confirmed the specific expression of VSNL1 in
hPSC-SAN cells and their absence in the human embryonic stem cells (hESC) derived ventricular myocytes.
Using CRISPR-Cas9 technology, the applicant has generated knock-out models of VSNL1 gene in hESC. The
applicant will use hESC lines carrying VSNL1 null mutation to generate hPSC-SAN lacking functional VSNL1.
Analyzing beating rate, calcium activity, and action potential using patch clamp will elucidate the cell type-specific
role of VSNL1 in human SAN biology. Third, perform functional studies to test the role of VSNL1 in hPSC-SAN
response to adrenergic and cholinergic signals. Recent studies support that VSNL1 is involved in
neurotransmitter receptor trafficking. The applicant will generate loss of function (LoF) and gain of function (GoF)
VSNL1 variants in hESC using the previously established protocols. The applicant will generate SAN cells from
hESCs carrying knock-out, GoF, or LoF VSNL1 variants to study the effect of various adrenergic and cholinergic
neurotransmitters on SAN cells’ beating rate, calcium, activity, and action potential.
项目概要
在心脏中,起搏器或窦房结细胞 (SAN) 启动并维持有节奏的跳动模式,可以
对外部刺激做出反应,包括神经递质、旁分泌和内分泌信号。除了它的
临床重要性,静息心率与跨物种的寿命相关,并且与
几项大型流行病学研究中个体的寿命。尽管它们在人类健康和
生理学上,维持精确节律振荡的确切细胞内机制尚不清楚,因为
心脏中这些细胞的接触受到限制。主要研究者假设基因表达
对人类窦房结细胞的分析将识别人类的细胞和生理特征
起搏功能。最近的技术已经能够从胚胎中生成功能性的人类 SAN
干细胞 (hPSC-SAN) 并在单细胞水平上进行分子表征。 VSNL1,一种钙
传感蛋白,被鉴定为 SAN 细胞特有的标记。我假设 VSNL1 是独一无二的
参与心率调节。分析VSNL1基因的遗传变异及其对心率的影响
在大型生物库中的研究将能够验证该蛋白质在心率生理学中的功能作用。申请人
将使用大型生物库队列和基因工程人类胚胎干细胞来追求以下目标
目的:首先,确定 VSNL1 基因变异与心血管生理学之间的关联
几个大型生物库。英国生物银行 (UKBB) 队列的初步数据表明,
VSNL1 基因和基线心率的遗传变异。申请人将进一步研究VSNL1的效果
心率随运动、心房和心室功能(心脏 MRI)以及心血管发病率的变化
UKBB 和其他更多样化群体的死亡率结果。二、了解遗传的影响
hPSC-SAN 分子和电生理特征中与 UKBB 心率相关的变异
体外细胞。初步数据显示,申请人已成功确认VSNL1在
hPSC-SAN 细胞及其在人胚胎干细胞 (hESC) 衍生的心室肌细胞中的缺失。
申请人利用CRISPR-Cas9技术,在hESC中建立了VSNL1基因的敲除模型。这
申请人将使用携带VSNL1无效突变的hESC系来产生缺乏功能性VSNL1的hPSC-SAN。
使用膜片钳分析搏动率、钙活性和动作电位将阐明细胞类型特异性
VSNL1 在人类 SAN 生物学中的作用。第三,进行功能研究以测试 VSNL1 在 hPSC-SAN 中的作用
对肾上腺素能和胆碱能信号的反应。最近的研究支持 VSNL1 参与
神经递质受体贩运。申请人将产生功能丧失(LoF)和功能获得(GoF)
使用先前建立的协议的 hESC 中的 VSNL1 变体。申请人将生成 SAN 单元
携带敲除、GoF 或 LoF VSNL1 变体的 hESC,用于研究各种肾上腺素能和胆碱能的作用
神经递质对 SAN 细胞跳动率、钙、活动和动作电位的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ZANIAR GHAZIZADEH其他文献
ZANIAR GHAZIZADEH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 8.08万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 8.08万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 8.08万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 8.08万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 8.08万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 8.08万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 8.08万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 8.08万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 8.08万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 8.08万 - 项目类别:














{{item.name}}会员




